Arun J Sanyal

Sep 3, 2024 | nature.com | Faiez Zannad |Arun J Sanyal |Veronica Miller

AbstractThe intersection of cardiovascular disease, metabolic disorders and chronic kidney disease represents a complex clinical picture challenging healthcare systems worldwide. Metabolic-dysfunction-associated steatotic liver disease (MASLD) often manifests sequentially or concomitantly with these diseases, and may share underlying mechanisms and risk factors.

Jul 19, 2024 | nature.com | Zhila Semnani-Azad |Mario L. Morieri |John Dennis |Claudia Langenberg |Michèle Ramsay |Arun J Sanyal | +6 more

AbstractPrecision medicine should aspire to reduce error and improve accuracy in medical and health recommendations by comparison with contemporary practice, while maintaining safety and cost-effectiveness. The etiology, clinical manifestation and prognosis of diseases such as obesity, diabetes, cardiovascular disease, kidney disease and fatty liver disease are heterogeneous.

Jul 15, 2024 | healio.com | Arun J Sanyal |Heather Biele

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. To put it simply, diabetes and steatotic liver disease are joined at the hip. They are part of the same biological process that involves multiple organs, connected by the concept of metabolic flexibility — or lack thereof.

Jun 10, 2024 | nature.com | Arun J Sanyal

AbstractRetatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors. A 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2% with retatrutide 8 and 12 mg, respectively. The primary objective of this substudy was to assess mean relative change from baseline in liver fat (LF) at 24 weeks in participants from that study with metabolic dysfunction-associated steatotic liver disease and ≥10% of LF.

May 13, 2024 | onlinelibrary.wiley.com | Faiez Zannad |Université de Lorraine |Arun J Sanyal |Javed Butler

AST aspartate aminotransferase/aspartate transaminase CKD chronic kidney disease DALY disability-adjusted life year FIB4 Fibrosis-4 index GBD Global Burden of Disease GIP glucose-dependent insulinotropic peptide GLP-1 RA glucagon-like peptide 1 receptor agonist MACE major adverse CV event MASH metabolic dysfunction-associated steatohepatitis MASLD metabolic dysfunction-associated steatotic liver disease MOSAIC Metabolic multi Organ Science Accelerating Innovation in Clinical Trials MRA...